New combo aims to tackle Hard-to-Treat colorectal cancer
NCT ID NCT07229872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of two drugs—aipalolitovorelizumab and fruquintinib—in 18 people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants will receive the drugs in 3-week cycles until the cancer progresses or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aipalolitovorelizumab (QL1706) and fruquintinib
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
What could go wrong
This is a very small, early-phase trial with only 18 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••